A5031481733- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Ethics and Legal Issues in Pediatric Healthcare
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Surgical site infection prevention
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Vascular Tumors and Angiosarcomas
- Tumors and Oncological Cases
- Family Support in Illness
- Renal and related cancers
- Cardiac tumors and thrombi
- Palliative Care and End-of-Life Issues
- Cutaneous Melanoma Detection and Management
- COVID-19 Clinical Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer-related molecular mechanisms research
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Radiation Therapy and Dosimetry
- Migration, Health and Trauma
Fondazione IRCCS Istituto Nazionale dei Tumori
2016-2025
Avantea
2024
European Institute of Oncology
2024
Luigi Sacco Hospital
2021
San Raffaele University of Rome
2011
Data on BRAF/MEK inhibitors in pediatric and adolescent melanoma patients are limited. We report data of treated with dabrafenib/trametinib for compassionate use at our institution. From January 2020, four Stage III two IV disease were treated. Our demonstrates that targeted therapy children adolescents is safe achieves survival rates comparable to those observed adults. These findings support granting young adult-onset tumors access use, as well increasing their inclusion clinical trials....
Abstract The rapid spread of coronavirus disease 2019 epidemic in Italy, particular the Milan focal point, required drastic measures and led to panic population. While our center we did not change approach treatment young patients with cancer, developed a qualitative survey assess their perception risk level stress. showed that relatively large proportion felt personally at severe complications. We believe need adequately inform patients, focusing on hygienic personal protection prompt...
The potential impact of diagnostic delays on patients' outcomes is a debated issue in pediatric oncology and discordant results have been published so far. We attempted to tackle this by analyzing prospective series 351 consecutive children adolescents with solid malignancies using innovative statistical tools.To address the nonlinear complexity association between symptom interval overall survival (OS), regression tree algorithm was constructed sequential binary splitting rules used...
Andrea Ferrari, Michela Casanova, Stefano Chiaravalli, Chiara Magni, Roberto Luksch, Monica Terenziani, Filippo Spreafico, Daniela Polastri, Cristina Meazza, Serena Catania, Elisabetta Schiavello, Veronica Biassoni, Marta Podda, Luca Bergamaschi, Nadia Puma, Carla Moscheo, Giacomo Gotti, Maura Massimino, Fondazione IRCCS Istituto Nazionale Tumori; Laura Veneroni, Carlo Alfredo Clerici, University of Milan, Italy.
The prognosis for patients with metastatic rhabdomyosarcoma (RMS) remains largely unsatisfactory despite the adoption of intensive multimodal therapy. To assess role different treatments adopted over years, we retrospectively analyzed a cohort <21 years old RMS, treated from 1990 to 2020 at referral center pediatric sarcomas.Patients were using approach that included surgery, radiotherapy, and chemotherapy (both high-dose maintenance therapy in some cases). type radiotherapy administered...
Abstract Background Central nervous system (CNS) tumors are the leading cause of cancer-related deaths in children aged 0–14 years. Despite significant efforts, targeted therapies based on identified pathways have not improved survival rates. Research has shown that gut microbiota (GM) can influence brain tumor cell proliferation, suggesting microbiota-gut-brain axis plays a role CNS cancer. Our study aims to assess whether GM composition pediatric exhibits specific characteristics. Methods...
ABSTRACT Background Various projects dedicated specifically to adolescents and young adults (AYA) with cancer have been developed in recent years. A critical aspect of such programs is the ability demonstrate its value, therefore how measure desired outcomes. Methods list metrics consider for demonstrating advantages an AYA program was identified used assess activity Youth Project operating at Pediatric Oncology Unit Istituto Nazionale Tumori Milan. Results The number newly diagnosed...
Abstract Cutaneous melanoma is rare in children and, like other very pediatric tumors, it suffers from a shortage of knowledge and clinical expertise. The management often challenging. Its pathological diagnosis may be difficult, there no standard treatment. In the absence specific treatment guidelines, young patients are generally treated following same principle as for adults, but concern remains about their access to trials new drugs, which have been shown dramatically change natural...
Abstract In the era of big data, young patients may be overwhelmed by artificial intelligence‐based tools, like chatbots. Five clinical experts were asked to evaluate performance most currently used chatbots in providing information on a rare cancer affecting people, rhabdomyosarcoma. Generally speaking, despite their high giving general about disease, these considered inadequate suggestions treatments and specialized centers, also lacking “sensitivity.” Efforts are planned pediatric...
Abstract Background We applied the strategy for M+ medulloblastoma across all high-risk subgroups, including LC/A histology, TP53 mutations, and MYC/MYCN amplification. Methods Patients over 3 years old received, after surgery, staging histo-biological analysis, sequential high-dose-methotrexate(HD-MTX), high-dose-etoposide(HD-VP16), high-dose-cyclophosphamide(HD-Cyclo), high-dose-carboplatin(HD-Carbo). Hyperfractionated-accelerated-radiotherapy–craniospinal(HART-CSI), administered twice...
Malignant peripheral nerve sheath tumor (MPNST) is one of the most common nonrhabdomyosarcoma soft tissue sarcomas encountered in pediatric age, and it generally characterized by poor outcome, particularly for relapsing patients.This study considered 73 patients <21 years age with MPNST observed among 120 enrolled Italian protocols from 1979 to 2004. With aim possibly establishing a risk-adapted stratification, patients' outcome was examined using univariate multivariate analysis based on...
Adolescents and young adults (AYA) with rhabdomyosarcoma (RMS) form a subgroup of patients whose optimal clinical management access to care remain challenge survival lacks behind that children diagnosed histologically similar tumors. Understanding the tumor biology differentiates from AYA-RMS could provide critical information drive new initiatives improve final outcome. MicroRNA (miRNA) gene expression profiling (GEP) was evaluated in RMS cohort 49 15 non-neoplastic tissues. miRNAs analysis...
Rhabdomyosarcoma (RMS) is the most frequent soft tissue tumor in childhood and arises from immature mesenchymal cells committed to skeletal muscle differentiation. Anaplastic Lymphoma Kinase (ALK) a receptor tyrosine kinase aberrantly expressed several cancers. Moreover, ALK full-length protein has been observed RMS, although its clinical functional significance yet controversial. The role of relevance were investigated selected cohort 74 FFPE pediatric RMS panel cell lines, evaluating gene...
Rhabdomyosarcomas (RMSs) are the most frequent soft tissue sarcoma in children and adolescents, defined by skeletal muscle differentiation status of FOXO1 fusions. In pediatric malignancies, particular RMS, scant controversial observations reported about PD-L1 expression as a putative biomarker few immune checkpoint clinical trials conducted. assessment was evaluated immunohistochemistry (IHC) utilizing two anti-PDL1 antibodies, pilot cohort 25 RMS. Results were confirmed primary commercial...
Objective. The aim of the present study is to understand which areas sexuality were regarded as most important and/or problematic among adolescents with cancer.Methods. A questionnaire was administered adolescent and young adult patients who had been receiving treatments at Pediatric Oncology Unit our Institution, for least 2 months, those in follow-up completed their no more than two years previously. devised investigate patients' experiences various areas, i.e. personal relations, sexual...
Effective new drugs are urgently needed for desmoplastic small round cell tumor (DSRCT), an extremely rare and aggressive disease with a generally poor prognosis. We describe two heavily-pretreated young patients advanced-stage DSRCT given third-line treatment combination of trabectedin irinotecan, based on our preclinical data demonstrating its effect patient-derived xenografts. This trabectedin-irinotecan showed limited toxicity. One patient had mixed response (overall stable disease), the...
This study reports the treatment feasibility and efficacy of a novel multiagent intensive program for young patients with desmoplastic small round cell tumor. series includes three should be seen as first suggestion integration dose density maintenance chemotherapy concept. The IrIVA regimen (irinotecan, ifosfamide, vincristine, actinomycin-D) is added-used at short interval between administrations-at more classic ifosfamide-based regimens. vinorelbine low-dose oral cyclophosphamide therapy...